Last update 12 Dec 2024

Infliximab

Last update 12 Dec 2024

Overview

R&D Status

Clinical Result

Translational Medicine

Overview

Basic Info

Drug Type

Monoclonal antibody

Synonyms

Avakine, CenTNF, Infliximab (Genetical Recombination)

+ [8]

Target

TNF-α

Mechanism

TNF-α inhibitors(Tumor necrosis factor α inhibitors)

Therapeutic Areas

Immune System DiseasesInfectious DiseasesCardiovascular Diseases+ [7]

Active Indication

Mucocutaneous Lymph Node SyndromeBehcet's uveitisErythrodermic psoriasis+ [17]

Inactive Indication

Axial SpondyloarthritisBerylliosisCachexia+ [12]

Originator Organization

Janssen Global Services LLC

Active Organization

Mitsubishi Tanabe Pharma Corp.Janssen Biologics BV

Janssen Biotech, Inc.

+ [2]

Inactive Organization

Merck Sharp & Dohme Corp.Schering-Plough Corp.

Nichi-Iko Pharmaceutical Co., Ltd.

+ [2]

Drug Highest PhaseApproved

First Approval Date

US (24 Aug 1998),

Crohn Disease

RegulationFast Track (US), Accelerated Approval (US), Orphan Drug (JP), Orphan Drug (US)

Gene Sequence

Sequence Code 69035L

Source: *****

Sequence Code 69038H

Source: *****

412

Clinical Trials associated with Infliximab

NCT06614387 / Not yet recruitingPhase 3IIT

Assessment of Safety and Efficacy of Vedolizumab in Pediatric Uclerative Colitis in Comparison With Standard Biological Therapy With Infliximab

This is a multicenter, double-blind, randomized study to compare the safety, effectiveness and immunogenicity (antibodies against drug) of two biological drugs administered intravenously - vedolizumab (a drug not registered in pediatric patients) and infliximab (used as standard therapy), in pediatric patients with UC aged 6-18 years.
Before enrollment to the study, informed consent must be obtained from the participant's legal guardian and, additionally, from the participant aged >16 years before any procedures are performed.

Start Date01 Oct 2024

Sponsor / Collaborator

$Instytut \"Pomnik - Centrum Zdrowia Dziecka\"$ Instytut \"Pomnik - Centrum Zdrowia Dziecka\"

NCT06601595 / Not yet recruitingNot ApplicableIIT

Spondyloarthropathy in Inflammatory Bowel Disease Patients and Evaluation of Its Response to TNF Inhibitors in Assiut University Hospital

Prevelance of axial spondylosis arthritis in inflammatory bowel disease and its RESPONSE to tumour necrosis factor (TNF) inhibitors TREATMENT

Start Date01 Oct 2024

Sponsor / Collaborator

Assiut University

NCT06453317 / Not yet recruitingPhase 2IIT

Comparison of Ustekinumab, Infliximab and Combination Therapy in Moderately to Severely Active Ulcerative Colitis (COMBO-UC)

The goal of this clinical trial is to learn if combined therapy with infliximab and ustekinumab works better than using these drugs alone in adult patients with ulcerative colitis. It will also learn about the safety of this combination. The main questions it aims to answer are:
Does the combination therapy improve the symptoms and heal the intestine quicker and better than these drugs administered alone? Does the combination therapy improve the quality of life better than these drugs administered alone? What medical problems do participants have when taking the combination therapy?
Participants:
Patients diagnosed with UC will be qualified to biologic therapy (infliximab/ustekinumab/infliximab + ustekinumab).
Visit the clinic in stated periods for assessment and to apply medication. Take drugs based on the schedule.

Start Date01 Jul 2024

Sponsor / Collaborator

Medical University of Lodz

[+3]

100 Clinical Results associated with Infliximab

100 Translational Medicine associated with Infliximab

100 Patents (Medical) associated with Infliximab

14,499

Literatures (Medical) associated with Infliximab

01 Dec 2025·Current Rheumatology Reports

An Update on Kawasaki Disease

Review

Author: Goel, Anurag Ratan ; Yalcindag, Ali

PURPOSE:

To summarize advances in research on the epidemiology, pathogenesis, diagnosis, and treatment of Kawasaki Disease (KD), a systemic inflammatory illness of unknown etiology that affects children globally.

RECENT FINDINGS:

The epidemiology of KD was affected by the COVID-19 pandemic and advances in molecular immunology and machine learning have enabled research into its pathogenesis. There is ongoing research into agents that can be used to intensify initial treatment and accumulating evidence supporting the use of certain rescue regimens for refractory disease over others. There is promise surrounding a new coronary artery aneurysm prediction model. Research into the post-acute morbidity of KD continues. The COVID-19 pandemic temporarily reduced the incidence of KD. The NLRP3 inflammasome plays a key role in KD pathogenesis. Intensified initial treatment benefits high-risk patients, yet no intensification regimen shows superiority over another. Corticosteroids, infliximab, or combination therapy with IVIg plus another agent may be superior rescue regimens compared to IVIg alone for refractory KD. The Son score, developed in North America, predicted coronary artery lesions in Japanese and Italian cohorts. Patients with a history of KD may carry long-term physical and emotional burdens that persist into adulthood yet appear to have typical neurocognitive development. Successful transition to adult healthcare presents a challenge.

01 Apr 2025·DEN open

Colitis in a patient with familial Mediterranean fever: Is it Crohn's disease or ulcerative colitis?

Article

Author: Shimodate, Yuichi ; Nishimura, Naoyuki ; Takezawa, Rio ; Matsueda, Kazuhiro ; Mouri, Hirokazu ; Hoshi, Ayano ; Matsumoto, Takayuki ; Mizuno, Motowo ; Gotoda, Tatsuhiro

Abstract:

A 24‐year‐old woman was referred to our hospital with joint pain, fever, abdominal pain, and diarrhea. A colonoscopy revealed longitudinal ulcers with a cobblestone appearance throughout the entire colon, suggestive of Crohn's disease. However, treatment with 5‐aminosalicylic acid, azathioprine, and infliximab failed to achieve clinical remission. A colonoscopy 5 months later revealed a diffusely spreading granular mucosa without visible vasculature, compatible with active ulcerative colitis. Based on these serial changes in colonic lesions, we tested the patient for MEFV gene mutations and found variants E148Q and L110P in exon 2. Administration of colchicine resulted in complete clinical remission. Our experience suggests that drastic changes in the features of colonic inflammation may be a clue to the diagnosis of enterocolitis associated with familial Mediterranean fever.

01 Feb 2025·Biomaterials advances

A macromolecule infliximab loaded reverse nanomicelles-based transdermal hydrogel: An innovative approach against rheumatoid arthritis

Article

Author: Rehman, Asim.ur. ; Shah, Kifayat Ullah ; Ahmed, Naveed ; Mir, Maria ; Khan, Dildar ; Muhammad, Adil ; Rehman, Asim Ur

Infliximab (IFX) is used as a biotherapeutic agent for the treatment of rheumatoid arthritis (RA); however, its biological activity is lost orally because of variations in gastric pH and enzymatic degradation, and reduced bioavailability. The authors have tried to improve the efficacy of macromolecule delivery through transdermal route. Polycaprolactone-Polyethylene glycol-Polycaprolactone (PCL-PEG-PCL) triblock copolymer previously synthesized and was used as an efficient carrier for the preparation of IFX loaded reverse nanomicelles (IFX-RNMs). The RNMs were fabricated via nanoprecipitation technique, characterized and then were incorporated into a Carbopol-based hydrogel with eucalyptus oil (EO) as a penetration enhancer. The optimized RNMs had a particle size of 72.32 nm and an encapsulation efficiency of 83 %. In vitro release, exhibited a sustained pattern of IFX from the prepared carrier system, ex-vivo skin permeation and fluorescence microscopic studies revealed that IFX-RNMs loaded hydrogel with EO markedly improved permeation. An in vivo study was carried out on a CFA-induced RA mice model that revealed significant improvements in the results of behavioral parameters, biochemical assays, histopathological and radiological analysis. Overall, the results concluded that the IFX-RNMs loaded hydrogel can be used as a suitable approach for treating RA.

158

News (Medical) associated with Infliximab

09 Dec 2024

·www.businesswire.com

TNF Pharmaceuticals Presents Statistically Significant Phase 2a Trial Results for Novel Sarcopenia/Frailty Treatment at Prestigious International Conference

BALTIMORE--( BUSINESS WIRE )--TNF Pharmaceuticals, Inc. (Nasdaq: TNFA) (“TNFA” or the “Company”), a clinical stage biopharmaceutical company committed to developing novel oral therapies for autoimmune and inflammatory conditions, today announced that significant positive topline results from a Phase 2a study of its lead drug candidate MYMD-1® (isomyosamine) was presented at a prestigious international congress of global experts in sarcopenia and related disorders held December 6–8, 2024 in Washington, D.C. “In our view, MYMD-1 could become a consequential therapeutic solution for patients not served by current TNF-alpha inhibitors,” said Mitchell Glass, M.D., President and Chief Medical Officer of TNFA. “With no FDA-approved treatments available to sarcopenia/frailty patients that target this disease itself, there is a large unmet medical need for effective therapies. Plus, the estimated $3 billion sarcopenia treatment market is just a subset of the broader TNF inhibitor market which was estimated to be $40 billion in 2024. “Based on the positive results from our MYMD-1 Phase 2a study, we are set to launch a Phase 2b study in sarcopenia/frailty early in the first quarter of 2025,” Dr. Glass added. The presentation, ‘Isomyosamine for the Treatment of Sarcopenia in Elderly Population,’ describes the results of a double-blind, placebo-controlled study in patients aged 65 years or older with chronic inflammation associated with sarcopenia/frailty. Subjects in the trial who were given once daily oral doses of MYMD-1 showed significant decreases in several biomarkers attributed to chronic inflammation, including tumor necrosis factor-alpha (TNF-α) (P=0.008), Interleukin-6 (IL-6) (P=0.03) and soluble TNF-α receptor 1 (sTNFR1) (P=0.02) at several timepoints throughout the 28 days of treatment. No serious adverse events were reported. The global market value for TNF inhibitors was estimated to be $39.7 billion for 2024. Growing at an expected 3.6% CAGR for the next five years, the TNF inhibitor market is expected to reach $47.3 billion by 2029. 1 Sarcopenia is the progressive loss of muscle mass and strength primarily due to aging. Based on conservative calculations, at least 50 million people were affected by sarcopenia in 2018, and the disease is projected to affect over 200 million over the next four decades due to the growing elderly population. 2 The sarcopenia treatment market is estimated to be $3.07 billion in 2024 and is expected to grow at a CAGR of 4.48% to $4.02 billion by 2029. 3 Approximately 10% to 16% of the elderly worldwide suffer from sarcopenia. 4 In addition to the elderly, sarcopenia is estimated to affect more than 1 in every 10 young adults of most ethnicities. 5 With no FDA-approved treatments for sarcopenia itself, as opposed to its symptoms, the estimated $40+ billion in related hospitalization costs is a considerable economic burden on the U.S. healthcare system. 6 The 17th International Conference of the Society on Sarcopenia, Cachexia, & Wasting Disorders joins researchers, clinicians, academic experts, investigators and industry leaders from around the world. SCWD is a non-profit scientific organization comprised of an international and multidisciplinary group of healthcare professionals primarily active in these fields. About MYMD-1 ® MYMD-1® (isomyosamine) is a novel plant alkaloid small molecule shown to regulate the immuno-metabolic system through the modulation of numerous pro-inflammatory cytokines including TNF-alpha (TNF-α), an immune cell signaling protein and inflammatory cytokine responsible for inducing and maintaining the inflammatory process. TNF-α is located upstream of a cascade of molecular signals that induces inflammation and helps activate the process of aging. Many in vivo and in vitro studies have shown that TNFα plays a causative role in the pathogenesis of various age-related diseases. About TNF Pharmaceuticals, Inc. TNF Pharmaceuticals, Inc. (Nasdaq: TNFA) (formerly known as MyMD Pharmaceuticals, Inc.), a clinical stage pharmaceutical company committed to extending healthy lifespan, is focused on developing two novel therapeutic platforms that treat the causes of disease rather than only addressing the symptoms. MYMD-1® is a drug platform based on a clinical stage small molecule that regulates the immune system to control TNF-α, which drives chronic inflammation, and other pro-inflammatory cell signaling cytokines. MYMD-1 is being developed to treat diseases and disorders marked by acute or chronic inflammation. The Company’s second drug platform, Supera-CBD, is being developed to treat chronic pain, addiction and epilepsy. Supera-CBD is a novel synthetic derivative of cannabidiol (CBD) and is being developed to address and improve upon the rapidly growing CBD market, which includes both FDA approved drugs and CBD products not currently regulated as drugs. For more information, visit www.tnfpharma.com . Cautionary Statement Regarding Forward-Looking Statements This press release may contain forward-looking statements. These forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause actual results, performance or achievements to be materially different from any expected future results, performance, or achievements. Forward-looking statements speak only as of the date they are made and neither the Company nor its affiliates assume any duty to update forward-looking statements. Words such as “anticipate,” “believe,” “could,” “estimate,” “expect,” “may,” “plan,” “will,” “would’’ and other similar expressions are intended to identify these forward-looking statements. Important factors that could cause actual results to differ materially from those indicated by such forward-looking statements include, without limitation: the Company’s ability to maintain compliance with the Nasdaq Stock Market’s listing standards; the timing of, and the Company’s ability to, obtain and maintain regulatory approvals for clinical trials of the Company’s pharmaceutical candidates; the timing and results of the Company’s planned clinical trials for its pharmaceutical candidates; the amount of funds the Company requires for its pharmaceutical candidates; increased levels of competition; changes in political, economic or regulatory conditions generally and in the markets in which the Company operates; the Company’s ability to retain and attract senior management and other key employees; the Company’s ability to quickly and effectively respond to new technological developments; and the Company’s ability to protect its trade secrets or other proprietary rights, operate without infringing upon the proprietary rights of others and prevent others from infringing on the Company’s proprietary rights. A discussion of these and other factors with respect to the Company is set forth in the Company’s Annual Report on Form 10-K for the year ended December 31, 2023, filed by the Company on April 1, 2024, and subsequent reports that the Company files with the Securities and Exchange Commission. Forward-looking statements speak only as of the date they are made, and the Company disclaims any intention or obligation to revise any forward-looking statements, whether as a result of new information, future events or otherwise. 1 Mordor Intelligence, TNF Inhibitors Market Size (2024 - 2029) 2 Biology , Sarcopenia Is Associated with an Increased Risk of Postoperative Complications… (2023) 3 Mordor Intelligence, Sarcopenia Treatment Market Size & Share Analysis - Growth Trends & Forecasts (2024 - 2029) 4 Metabolism journal, Epidemiology of sarcopenia: Prevalence, risk factors, and consequences (2023) 5 Metabolism journal, Sarcopenia in youth (2023) 6 Journal of Frailty & Aging, Economic Impact of Hospitalizations in US Adults with Sarcopenia (2019)

Phase 2Clinical Result

03 Dec 2024

·www.prnewswire.com

InsightRX to Present Latest Research and Platform Enhancements at ASHP 2024 Midyear

SAN FRANCISCO, Dec. 3, 2024 /PRNewswire/ -- InsightRX – the leader in Bayesian model-informed precision dosing (MIPD) software – today announced it will attend the ASHP 2024 Midyear Clinical Meeting & Exhibition as both an exhibitor and presenter. The meeting is scheduled for Dec. 8-12 at the Ernest N. Morial Convention Center in New Orleans. ASHP 2024 is organized by the American Society of Health-System Pharmacists and will include vendor exhibits, educational sessions, poster presentations, and networking opportunities for pharmacy professionals. Representatives from the InsightRX team will be at booth 1340 in the exhibition hall (available on Monday Dec 9 and Tuesday Dec 10 from 11am - 3pm, and Wed Dec 11 from 11am - 2pm) to meet with visitors and discuss product updates, new features, and benefits of Bayesian MIPD adoption. Additionally, InsightRX Senior Director of Product & Customer Experience Jonathan Faldasz, PharmD, BCPS, will present a poster from the InsightRX team on Monday, Dec. 9, from 2-3:30 p.m. The title of the poster is Proposed Update to the Cockcroft-Gault Equation for Patients with Low Serum Creatinine: Results from a Massive Multi-Site Dataset. This study evaluated the accuracy of the Cockcroft-Gault equation–long regarded as the gold standard for estimating renal function–in patients with serum creatinine levels below 1 mg/dL. By analyzing data from nearly 100,000 patients, the InsightRX team identified significant inaccuracies in the equation's predictions for this population. In response, they developed a modified equation incorporating adjusted serum creatinine, which demonstrated greatly improved accuracy. The poster will detail these findings and their implications for clinical practice. Front and center will be demonstrations of a new feature to the Nova platform, InsightRX Gemini, designed to eliminate complexities of manual PK model selection. InsightRX Gemini automatically chooses the best-performing PK model for the patient, based on four common covariates, and was built analyzing approximately 400,000 vancomycin treatment courses contained in the Nova data lake. When compared to commonly available PK models (seen in "freeware" and various other applications), InsightRX Gemini: increases dosing accuracy for individual patients up to 47.2% increases precision by up to 25% decreases bias by up to 93% Overall, MIPD dosing activities have increased for a variety of therapeutic areas and hold promise for enhancing workflows and producing more accurate dosing and improved outcomes. In addition to vancomycin, InsightRX offers numerous other Drug Modules, which the team will also present at the exhibition. Several of these were highlighted in recent studies, thought leadership articles, and blog posts by the InsightRX team over the past year, including: Antifungals – Posaconazole is a pharmacotherapeutic pillar for prophylaxis and treatment of invasive fungal diseases. Dose individualization is critical to achieving adequate antifungal exposure associated with improved outcome. InsightRX validated an MIPD strategy for posaconazole for its fit-for-purpose, an important first step toward dosage optimization with the goal to improve antifungal treatment in clinical practice. Beta-lactams – Therapeutic drug monitoring (TDM) can improve PK/PD target attainment of beta-lactam levels and optimize dosing in vulnerable populations. There are still several barriers to widespread adoption of TDM of beta-lactams into routine clinical practice, however, beta-lactam TDM has great potential to improve patient care by optimizing antibiotic dosing, especially in high-risk populations. Solid organ transplant – Therapeutic drug monitoring is essential with tacrolimus, one of the key immunosuppressive agents used after solid organ transplant. Although most transplant centers rely on trough concentrations drawn immediately before the dose, evidence shows a poor correlation between tacrolimus trough concentrations and outcomes. A 2019 tacrolimus guidance document concludes that Bayesian estimation may be a better way to improve future tacrolimus TDM. Bone marrow transplant – Dose personalization improves patient outcomes for many drugs with a narrow therapeutic index and high inter-individuality variability, including busulfan. In a simulated study, InsightRX demonstrated that while area under the curve (AUC) estimates between the two methods showed good correlation, the maximum a posteriori Bayesian (MAP) approach led to higher target attainment for busulfan dosing. Anticoagulants – Heparin is a lifesaving mainstay of anticoagulation in patients at high risk of coagulation-related morbidity and mortality. Yet most hospitals struggle to keep their patients at a target heparin exposure, which can result in increased morbidity and mortality from both clotting and bleeding events. Several exciting advances in the use of MIPD for heparin would allow clinicians to better individualize therapy for each treatment course. Inflammatory bowel disease – Efficacy of infliximab in children with inflammatory bowel disease can be enhanced when serum concentrations are measured and further dosing is adjusted to achieve and maintain a target concentration. A recent collaborative study showed that a population pharmacokinetic model may help to predict an individual's infliximab dose requirement. "InsightRX has enjoyed a year of real growth and accomplishment and we're excited to meet with our colleagues at ASHP in New Orleans to discuss what we've learned and how we plan to continue improving dosing safety and accuracy," said Sirj Goswami, PhD, CEO and cofounder of InsightRX. "Model-informed precision dosing holds great promise for contributing to better clinical outcomes and operational efficiency." About InsightRX InsightRX is a healthcare technology company providing a cloud-based clinical decision support platform that applies quantitative pharmacology and AI to enhance therapeutic decision-making from phase I drug development to point of care. The company's platform provides an individualized, predictive understanding of a patient's response to treatment which enables an enhanced understanding of dose-effect response and toxicity for clinicians to improve medication effectiveness. Media Contact Michelle Noteboom Amendola Communications for InsightRX [email protected] SOURCE InsightRX WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

21 Nov 2024

·www.outsourcing-pharma.com

Phase 3 win for Protagonist Therapeutics with oral plaque psoriasis drug

The phase 3 ICONIC-LEAD study showed that icotrokinra, a peptide drug that blocks the interleukin (IL)-23 receptor, was able to induce significant clearance of psoriatic plaques. The drug is being developed in conjunction with Johnson & Johnson and Protagonist will earn $115 million as a milestone payment from the big pharma for successful completing a phase 3 study. Protagonist has already earned $35 million due to acceptance of an NDA in psoriasis and $15 million for starting a phase 3 study in a second indication bringing its total milestone payments up to $165 million. The IGA scale is used to measure severity of psoriasis and ranges from 0 to 4, where 0 is clear skin and 4 indicates severe disease. The results from the trial show 65% of patients were able to achieve clear skin (an IGA score of 0 or 1) at week 16 versus only 8% of the placebo group. The PASI score relates to the amount of surface area on each part of the body that is covered by psoriasis plaques and also grades severity of the plaques. A score of 90 or more means that this has improved by 90% from the start of the study, which 50% of icotrokinra patients achieved versus only 4% of the placebo group. The effects of the drug improved with time and by week 24, 74% of patients had achieved clear skin and 65% achieved PASI90. Around 49% of people in the treatment and placebo group had some form of adverse event, showing no increase with icotrokinra treatment. "These positive phase 3 results confirm the compelling efficacy and safety trends that were observed with the previous Phase 2b FRONTIER-1 and -2 studies, highlighting icotrokinra's potential as a best-in-class oral agent providing an ideal combination of significant skin clearance with demonstrated tolerability in a once-daily pill for treating plaque psoriasis," said Dinesh Patel, President and CEO of Protagonist. googletag.cmd.push(function () { googletag.display('text-ad1'); }); "These results also continue to validate Protagonist's innovative peptide technology platform and its effectiveness in creating highly differentiated new chemical entities to address unmet needs in various disease areas." New options for a common skin disorder Psoriasis impacts around 2-3% of the world’s population. It is an autoimmune skin condition where the body produces too many skin cells following a triggering event that causes the immune system to start this overproduction. In people with psoriasis, immune cells secrete inflammatory biomarkers that cause the skin to overproduce keratinocytes and create plaques on the skin that are characteristic of plaque psoriasis, which accounts for 85-90% of people with the skin condition. There is no cure for psoriasis, but many treatments are available ranging from topical to systemic. The most effective of the systemic drugs tend to be injectable, such as the monoclonal antibody therapies infliximab or ustekinumab. Icotrokinra is aiming to be as effective as the injectable therapies but taking the oral route to reduce invasiveness and make the treatment easier for patients. Bristol Myers Squibb has a popular oral psoriasis medication Sotyktu (deucravacitinib), a tyrosine kinase 2 (TYK2) inhibitor, which was approved in 2022. Protagonist and J&J are hoping to compete for some of this market and phase 3 trials testing the two drugs head-to-head are in progress.

Phase 3Clinical ResultPhase 2Drug Approval

100 Deals associated with Infliximab

External Link

KEGG	Wiki	ATC	Drug Bank
D02598	Infliximab	L04AB02	DB00065

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Mucocutaneous Lymph Node Syndrome	JP	Mitsubishi Tanabe Pharma Corp.	21 Dec 2015
Behcet's uveitis	JP	Mitsubishi Tanabe Pharma Corp.	26 Jan 2007
Erythrodermic psoriasis	JP	Mitsubishi Tanabe Pharma Corp.	17 Jan 2002
Psoriasis vulgaris	JP	Mitsubishi Tanabe Pharma Corp.	17 Jan 2002
Pustular psoriasis	JP	Mitsubishi Tanabe Pharma Corp.	17 Jan 2002
Ankylosing Spondylitis	EU	Janssen Biologics BV	13 Aug 1999
Ankylosing Spondylitis	IS	Janssen Biologics BV	13 Aug 1999
Ankylosing Spondylitis	LI	Janssen Biologics BV	13 Aug 1999
Ankylosing Spondylitis	NO	Janssen Biologics BV	13 Aug 1999
Arthritis, Psoriatic	EU	Janssen Biologics BV	13 Aug 1999
Arthritis, Psoriatic	IS	Janssen Biologics BV	13 Aug 1999
Arthritis, Psoriatic	LI	Janssen Biologics BV	13 Aug 1999
Arthritis, Psoriatic	NO	Janssen Biologics BV	13 Aug 1999
Colitis, Ulcerative	EU	Janssen Biologics BV	13 Aug 1999
Colitis, Ulcerative	IS	Janssen Biologics BV	13 Aug 1999
Colitis, Ulcerative	LI	Janssen Biologics BV	13 Aug 1999
Colitis, Ulcerative	NO	Janssen Biologics BV	13 Aug 1999
Crohn's disease, active moderate	EU	Janssen Biologics BV	13 Aug 1999
Crohn's disease, active moderate	IS	Janssen Biologics BV	13 Aug 1999
Crohn's disease, active moderate	LI	Janssen Biologics BV	13 Aug 1999

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Behcet Syndrome	Phase 3	JP	Mitsubishi Tanabe Pharma Corp.	01 Jan 2012
Axial Spondyloarthritis	Phase 3	-	Merck Sharp & Dohme Corp.	01 Sep 2009
Polymyalgia Rheumatica	Phase 3	ES	Schering-Plough Corp.	01 Jun 2007
Myositis	Phase 3	-	Schering-Plough Corp.	05 Mar 2007
Hepatitis C, Chronic	Phase 3	-	Merck Sharp & Dohme Corp.	18 Jul 2005
Erythema Infectiosum	Phase 3	US	Schering-Plough Corp.	01 Mar 2005
Erythema Infectiosum	Phase 3	AT	Schering-Plough Corp.	01 Mar 2005
Erythema Infectiosum	Phase 3	BE	Schering-Plough Corp.	01 Mar 2005
Erythema Infectiosum	Phase 3	CA	Schering-Plough Corp.	01 Mar 2005
Erythema Infectiosum	Phase 3	DK	Schering-Plough Corp.	01 Mar 2005

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT02251041 (CAPITL, CTgov)	Phase 2	Reperfusion Injury	143	C1-Inhibitor+Epoprostenol+Infliximab+Melatonin+Alfa-tocopherol+Human recombinant erythropoietin+Glutathione	oeadxbczhm(euivwhpgmp) = bsdmurhozt uumtlqcepd (xomjcmmxgc, lkyohufmay - uzhfhmmrwp) View more	-	23 Aug 2024
EULAR2024 Manual	Not Applicable	Behcet Syndrome TNF-α	77	Infliximab	sbgsfonjvw(zxuovxlbpc) = oxhfibdgoq fivuzyqgbc (qadszfbyln ) View more	Positive	05 Jun 2024
EULAR2024 Manual	Not Applicable	Sarcoidosis ACE \| Il2Ra levels	18	Infliximab therapy	toqrkzvqan(tnpcsnkyrb) = eakppnuahu dlpnavgyfa (dtyaxezjhy ) View more	Positive	05 Jun 2024
EULAR2024 Manual	Not Applicable	Sarcoidosis Third line	36	Infliximab 5mg/kg	egdkagsplf(ikkntryfhu) = 77% of patients remained on treatment, 13.8% experienced non-severe adverse reactions, and only the 2.7% developed infective complications (TB). kehtzphgyv (iiaykbjcnq )	Positive	05 Jun 2024
EULAR2024 Manual	Not Applicable	Neurosarcoidosis Third line	40	Cyclophosphamide	ehxethfjrh(nfndunezsz) = clikyvueub hzroaqdwab (qdcbumgfpu ) View more	Positive	05 Jun 2024
				Infliximab	ehxethfjrh(nfndunezsz) = hpkipvchuf hzroaqdwab (qdcbumgfpu ) View more
EULAR2024	Phase 2	Behcet Syndrome	52	Infliximab	yyrhqpxook(ybjcyocjgo) = bocjfquqfy gtqjjktskj (uyswztocme ) View more	Positive	05 Jun 2024
				Cyclophosphamide	yyrhqpxook(ybjcyocjgo) = azdotunnyl gtqjjktskj (uyswztocme ) View more
EULAR2024	Not Applicable	Rheumatoid Arthritis	-	Biologic and targeted synthetic DMARDs	dvphejftzw(pcmoxgvcjt) = xhnktahned owdgnjkxub (jkzjjesdzx ) View more	-	05 Jun 2024
EULAR2024	Not Applicable	Rheumatoid Arthritis	-	biologic drugs (Obese patients)	mlzktdtmvf(ontavnqugr) = mfvyoasilj bewfdzfyyr (szpcnfbtzt ) View more	Negative	05 Jun 2024
				biologic drugs (Non-obese patients)	mlzktdtmvf(ontavnqugr) = pbwuazxtzx bewfdzfyyr (szpcnfbtzt ) View more
EULAR2024	Not Applicable	IL-17A	135	Adalimumab (ADA)	vxbauarcul(fzlzegkowo) = pudfyzysuv qwyzkfurea (ixtupsfugl )	Positive	05 Jun 2024
				Infliximab (IFX)	vxbauarcul(fzlzegkowo) = yixosftftx qwyzkfurea (ixtupsfugl )
Literature Manual	Not Applicable	Crohn Disease \| Colitis, Ulcerative Maintenance	-	infliximab	ivfszvqbjo(xfxddvigei) = There were no meaningful differences in efficacy outcomes at Week 54 by CT-P13 concentration tertiles at Week 54 between monotherapy and combination therapy groups in both studies. hantpbhsqo (rdsldczndq ) View more	-	25 Jan 2024
				infliximab + immunosuppressants

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis